The odds were 16% lower for men who underwent external beam radiotherapy/intensity modulated radiation therapy, however.
Overall decision regret for 16.9% of patients; more regret for RP than radiotherapy component.
Prostatectomy and radiotherapy with or without ADT reduced prostate cancer-specific and all-cause mortality rates.
No significant differences observed in standard oncologic outcomes and quality of life at 12 weeks.
Largest Asian series to date shows a 5-year biochemical recurrence-free survival rate of 76.4%.
Urologists in Australia less favorable toward adjuvant radiotherapy in 2015 vs 2012.
Reduced risk of positive surgical margins versus open prostatectomy for patients with pT2 disease only.
Greater visceral adipose tissue volume and density are associated with a lower the risk of biochemical recurrence.
De novo OAB — defined as urgency with or without frequency and nocturia — developed in some patients.
Prostate cancer patients taking proton pump inhibitors also had pathologically higher stage disease.
Minimally invasive surgery is associated with a lower incidence of bladder neck contracture.
The chances of erectile function recovery improved when patients received radiation treatment more than 16 months after surgery.
An early, integrated approach led to less deterioration of erectile function after surgery.
Men with low-risk prostate cancer who undergo open or robot-assisted radical prostatectomy may have favorable oncological outcomes.
Study finds that 85% of all radical prostatectomies performed by urologists in 2013 were robot-assisted procedures, compared with just 22% in 2003.
Patients who performed preoperative pelvic floor muscle exercises had 36% lower risk of post-prostatectomy incontinence 3 months into their recovery.
This approach is feasible and is associated with low acute and late toxicity.
Insufficiency/deficiency of serum 25-OH D linked to increased odds of adverse pathology.
Advantages in terms of bother and pain surface in a prospective randomized trial comparing suprapubic tubes and urethral catheters.
A 12-gene androgen deprivation therapy resistance signature may help guide therapeutic decision making after radical prostatectomy.
Many men with low-risk disease being spared prostatectomy, radiation, and androgen deprivation treatment.
Radiation treatment is associated with an increased risk of requiring minimally invasive urologic procedures.
Individual cognitive factors accounted for half of all contributing human factor nano-codes.
A PHI of 82 discriminated between patients with and without biochemical recurrence.
This effect appears to occur mainly in men who experience recurrence when they are younger than 65 and in those with low-risk cancer.
Gleason 9-10 tumors are associated with a greater risk of biochemical and clinical recurrence, but not overall survival.
Researchers report on a study in which survivors were followed up for a median of 14 years.
Researchers concluded that margin status is a surrogate for established risk criteria.
The most common cause is respiratory compromise.
The 10-year rates of biochemical and clinical recurrence are comparable to those of open surgery.
Renal and Urology News Articles
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
- PET/CT May Improve Imaging of Recurrent Prostate Cancer
- Adding MRI Does Not Boost Prostate Cancer Upgrading Rate
- Both High and Low Uric Acid Levels Tied to Higher Mortality
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)